The global CINV Existing and Pipeline Drugs market size was valued at US$ 1485.2 million in 2023. With growing demand in downstream market, the CINV Existing and Pipeline Drugs is forecast to a readjusted size of US$ 1866.7 million by 2030 with a CAGR of 3.3% during review period.
The research report highlights the growth potential of the global CINV Existing and Pipeline Drugs market. CINV Existing and Pipeline Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of CINV Existing and Pipeline Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the CINV Existing and Pipeline Drugs market.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on CINV Existing and Pipeline Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the CINV Existing and Pipeline Drugs market. It may include historical data, market segmentation by Type (e.g., Aloxi, Zofran Generic), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the CINV Existing and Pipeline Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the CINV Existing and Pipeline Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the CINV Existing and Pipeline Drugs industry. This include advancements in CINV Existing and Pipeline Drugs technology, CINV Existing and Pipeline Drugs new entrants, CINV Existing and Pipeline Drugs new investment, and other innovations that are shaping the future of CINV Existing and Pipeline Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the CINV Existing and Pipeline Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for CINV Existing and Pipeline Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the CINV Existing and Pipeline Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting CINV Existing and Pipeline Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the CINV Existing and Pipeline Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the CINV Existing and Pipeline Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the CINV Existing and Pipeline Drugs market.
Market Segmentation:
CINV Existing and Pipeline Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Segmentation by application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Key Questions Addressed in this Report
What is the 10-year outlook for the global CINV Existing and Pipeline Drugs market?
What factors are driving CINV Existing and Pipeline Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do CINV Existing and Pipeline Drugs market opportunities vary by end market size?
How does CINV Existing and Pipeline Drugs break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CINV Existing and Pipeline Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for CINV Existing and Pipeline Drugs by Country/Region, 2019, 2023 & 2030
2.2 CINV Existing and Pipeline Drugs Segment by Type
2.2.1 Aloxi
2.2.2 Zofran Generic
2.2.3 Kytril Generic
2.2.4 Emend
2.2.5 Akynzeo
2.2.6 SUSTOL
2.2.7 Rolapitant
2.3 CINV Existing and Pipeline Drugs Sales by Type
2.3.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global CINV Existing and Pipeline Drugs Sale Price by Type (2019-2024)
2.4 CINV Existing and Pipeline Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Diagnostic Centers Therapeutics
2.4.4 Hospital Pharmacies
2.4.5 Drugstores
2.5 CINV Existing and Pipeline Drugs Sales by Application
2.5.1 Global CINV Existing and Pipeline Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global CINV Existing and Pipeline Drugs Sale Price by Application (2019-2024)
3 Global CINV Existing and Pipeline Drugs by Company
3.1 Global CINV Existing and Pipeline Drugs Breakdown Data by Company
3.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Company (2019-2024)
3.1.2 Global CINV Existing and Pipeline Drugs Sales Market Share by Company (2019-2024)
3.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global CINV Existing and Pipeline Drugs Revenue by Company (2019-2024)
3.2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Company (2019-2024)
3.3 Global CINV Existing and Pipeline Drugs Sale Price by Company
3.4 Key Manufacturers CINV Existing and Pipeline Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CINV Existing and Pipeline Drugs Product Location Distribution
3.4.2 Players CINV Existing and Pipeline Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CINV Existing and Pipeline Drugs by Geographic Region
4.1 World Historic CINV Existing and Pipeline Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global CINV Existing and Pipeline Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic CINV Existing and Pipeline Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global CINV Existing and Pipeline Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global CINV Existing and Pipeline Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas CINV Existing and Pipeline Drugs Sales Growth
4.4 APAC CINV Existing and Pipeline Drugs Sales Growth
4.5 Europe CINV Existing and Pipeline Drugs Sales Growth
4.6 Middle East & Africa CINV Existing and Pipeline Drugs Sales Growth
5 Americas
5.1 Americas CINV Existing and Pipeline Drugs Sales by Country
5.1.1 Americas CINV Existing and Pipeline Drugs Sales by Country (2019-2024)
5.1.2 Americas CINV Existing and Pipeline Drugs Revenue by Country (2019-2024)
5.2 Americas CINV Existing and Pipeline Drugs Sales by Type
5.3 Americas CINV Existing and Pipeline Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CINV Existing and Pipeline Drugs Sales by Region
6.1.1 APAC CINV Existing and Pipeline Drugs Sales by Region (2019-2024)
6.1.2 APAC CINV Existing and Pipeline Drugs Revenue by Region (2019-2024)
6.2 APAC CINV Existing and Pipeline Drugs Sales by Type
6.3 APAC CINV Existing and Pipeline Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CINV Existing and Pipeline Drugs by Country
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country (2019-2024)
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country (2019-2024)
7.2 Europe CINV Existing and Pipeline Drugs Sales by Type
7.3 Europe CINV Existing and Pipeline Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CINV Existing and Pipeline Drugs by Country
8.1.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa CINV Existing and Pipeline Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Type
8.3 Middle East & Africa CINV Existing and Pipeline Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CINV Existing and Pipeline Drugs
10.3 Manufacturing Process Analysis of CINV Existing and Pipeline Drugs
10.4 Industry Chain Structure of CINV Existing and Pipeline Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CINV Existing and Pipeline Drugs Distributors
11.3 CINV Existing and Pipeline Drugs Customer
12 World Forecast Review for CINV Existing and Pipeline Drugs by Geographic Region
12.1 Global CINV Existing and Pipeline Drugs Market Size Forecast by Region
12.1.1 Global CINV Existing and Pipeline Drugs Forecast by Region (2025-2030)
12.1.2 Global CINV Existing and Pipeline Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CINV Existing and Pipeline Drugs Forecast by Type
12.7 Global CINV Existing and Pipeline Drugs Forecast by Application
13 Key Players Analysis
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Helsinn
13.2.1 Helsinn Company Information
13.2.2 Helsinn CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Helsinn Main Business Overview
13.2.5 Helsinn Latest Developments
13.3 Heron Therapeutics
13.3.1 Heron Therapeutics Company Information
13.3.2 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Heron Therapeutics Main Business Overview
13.3.5 Heron Therapeutics Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Tesaro
13.5.1 Tesaro Company Information
13.5.2 Tesaro CINV Existing and Pipeline Drugs Product Portfolios and Specifications
13.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Tesaro Main Business Overview
13.5.5 Tesaro Latest Developments
14 Research Findings and Conclusion
*If Applicable.